Icodec

Aka: Icodec, Awiqli, Insulin U-700

advertisement

II. Background

  1. Released and FDA approved in 2026, as the first weekly Basal insulin

III. Indications

  1. Type 2 Diabetes Mellitus on Basal insulin

IV. Contraindications

  1. Hypoglycemia risk

V. Mechanism

  1. Binds reversibly to Serum Albumin
  2. Slowly released in a depot effect that lasts for approximately 7 days
  3. Peak plasma concentration is reached 15 hours after dose

VI. Dosing

  1. New Insulin start
    1. Start 70 units once weekly and titrate dose on a weekly basis based on Glucose monitoring
  2. Switching from other daily Basal insulin (e.g. Insulin Glargine) use
    1. Week 1 Loading Dose = (prior Basal insulin dose) * 7 * 1.5 (round to nearest 10 units)
      1. Given the day after the last Basal insulin
    2. Week 2 Dose: (prior Basal insulin dose) * 7
    3. Titrate dose weekly based on Glucose monitoring
  3. Missed doses
    1. Within 4 days of missed dose
      1. Give dose and shift weekly dose to the day given
    2. More than 4 days from missed dose
      1. Skip dose and resume on upcoming next due date

VII. Resources

  1. Icodec (DailyMed)
    1. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5162b93e-5775-4581-a5e9-e8783ae0acd7

VIII. References

  1. (2026) Presc Ins 33(10): 5-6

Images: Related links to external sites (from Bing)

These images are a random sampling from a Bing search on the term "Icodec." Click on the image (or right click) to open the source website in a new browser window. Search Bing for all related images

Related Studies

Related Topics in Pharmacology

advertisement